Breast Cancer — FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer
Citation(s)
Phase II, Multicenter, Single Arm Trial to Assess the Feasibility of First Line Ribociclib in Combination With a Non Steroidal Aromatase Inhibitor in Elderly Patients With Hormone Receptor Positive/HER2 Negative Advanced Breast Cancer